Also trades as: 0JQ2.L (LSE) · $vol 0M
KALA NASDAQ
KALA BIO, Inc.
1W: -10.6%
1M: -73.7%
3M: +392.7%
YTD: +8.0%
1Y: -90.4%
3Y: -95.4%
5Y: -99.7%
$0.66
-0.01 (-1.55%)
Weekly Expected Move ±16.9%
$0
$1
$1
$1
$1
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$12.8M
52W Range0.59-1030
Volume45,086
Avg Volume140,488
Beta-2.36
Dividend—
Analyst Ratings
Company Info
CEOAvi Minkowitz
Employees6
SectorHealthcare
IndustryBiotechnology
IPO Date2017-07-20
Websitekalarx.com
1167 Massachusetts Avenue
Arlington, MA 02476
US
Arlington, MA 02476
US
781 996 5252
About KALA BIO, Inc.
Kala Bio, Inc. functions as a biopharmaceutical company dedicated to the creation and commercialization of new therapeutic solutions. The core of their strategy involves utilizing proprietary nanoparticle technology, specifically mucus penetrating particles (MPPs). Initially, their focus for these treatments is directed towards ophthalmic diseases. The company was established in 2009 by co-founders Justin Hanes, Robert S. Langer, and Colin R. Gardner, and its headquarters are located in Arlington, Massachusetts.
Latest News
12 Health Care Stocks Moving In Monday's After-Market Session
Kala Bio Celebrates Trump Executive Order as Game-Changer for Psychedelic Medicine
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
EXCLUSIVE: Penny Stock Kala Bio Transitions To Revenue Model With AI Platform Launch
12 Health Care Stocks Moving In Thursday's Intraday Session
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Purdy Brendan P. | 0 | — | 2026-01-30 | |
| Posen Hillel D. | 0 | — | 2026-01-30 | |
| Minkowitz Avraham | 0 | — | 2026-01-30 | |
| Colman Yonatan C. | 0 | — | 2026-01-30 | |
| Berger Chaim D. | 0 | — | 2026-01-30 |